Want to join the conversation?
Specialty biopharmaceutical company $MNK said it closed the acquisition of the global portfolio of three commercial-stage topical hemostasis drugs from $MDCO. The portfolio includes Recothrom Thrombin topical (Recombinant), PreveLeak Surgical Sealant, and Raplixa (Fibrin Sealant (Human)).
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.